OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Anthropic IPO Marketing Expected to Start in Mid-October 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Add as a preferred source on Google
PHOENIX, March 01, 2018 -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that company founder John N. Kapoor, Ph.D., has completed the previously announced formation of an independently controlled trust related to his ownership stake in the company. The trust has been publicly filed with the Securities and Exchange Commission by the company on a Current Report on Form 8-K.
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
| CONTACT: | Corporate Communications | Investor Relations |
| Joe McGrath | Jackie Marcus or Chris Hodges | |
| INSYS Therapeutics | Alpha IR Group | |
| 480-500-3101 | 312-445-2870 | |
| [email protected] | [email protected] |
